PTH-induced mobilization of cytosolic Ca 2ϩ in a human kidney cell line (HEK/W) occurring in the absence of cAMP stimulation was characterized and compared with that obtained in the same cells stably transfected by the PTH/PTH-related peptide (PTHrp) receptor (HEK/T). In both cell lines, N-terminal fragments of PTH and PTHrp induced a concentration-dependent biphasic stimulation in [Ca 2ϩ ] i in various cell types (1). In certain cells, however, PTH stimulates only one of the two transduction pathways (2, 3), demonstrating that the coupling of PTH receptor to signal transduction pathways in these cells is different from that in cells responding to PTH by both a stimulation of cAMP production and [Ca 2ϩ ] i . This observation raises the possibility that the pathways involved in intracellular calcium increases in one or the other cases might be different. Indeed, different mechanisms have been implicated in the stimulation of [Ca 2ϩ ] i by PTH, including an increase of intracellular calcium release in the absence (4 -6) or after stimulation of inositol phosphate (InsP s ) production (7, 8) , and the activation of calcium channels (9, 10). The molecular basis for these differing responses has not been fully characterized, and various hypotheses are still being considered. Such differences in responses could be due to the presence of multiple PTH/PTH-related peptide (PTHrp) receptor isoforms (1). However, a PTH/PTHrp receptor has been cloned (1, 12), and it was subsequently demonstrated that this receptor, when expressed in transfected cells, could increase both cAMP production and [Ca 2ϩ ] i (7, 12) . In studies performed using the cloned receptor, increases in [Ca 2ϩ ] i have been shown to occur in the presence (7, 8) and the absence (5, 6) of phospholipase C activation. Thus, for at least these responses, it is not necessary to invoke different receptor isoforms to explain the activation of different signal transduction pathways by PTH. Other possible mechanisms include differences in 1) the number of receptors expressed (13-15); 2) cellular signal transduction machinery (13); and 3) the agonist used [e.g. the utilization of N-terminal, midregion or C-terminal fragments of PTH or PTHrp (16 -18)].
I]PTHrP(1-34) could be detected. Amplification products for the PTH/PTHrp receptor 1, but no other isoforms, were detected by RT-PCR in HEK/W cells. As expected, HEK/T cells responded to PTH by a 500-fold stimulation in cAMP production and expressed large numbers of PTH/ PTHrp receptors, as shown by [ 125 I]PTHrp binding. These results demonstrate that the signal transduction pathways activated by PTH in HEK/W and HEK/T cells are different. Because the major difference in these cell lines is the number of PTH/PTHrp receptors expressed, these results suggest that the transduction of signals by the PTH/PTHrp receptor is controlled by receptor number in such a way that PTH stimulates an increase in intracellular calcium in the absence of stimulation of InsP s and cAMP production in cells expressing low levels of PTH/PTHrp receptor, but stimulates calcium release through an InsP s pathway and induces cAMP production in cells expressing large numbers of PTH/PTHrp receptors. The control of receptor number may be one of the mechanisms through which PTH effects are regulated. (Endocrinology 138: 5282-5292, 1997) P TH STIMULATES cAMP formation and increases the intracellular calcium concentration [Ca 2ϩ ] i in various cell types (1) . In certain cells, however, PTH stimulates only one of the two transduction pathways (2, 3) , demonstrating that the coupling of PTH receptor to signal transduction pathways in these cells is different from that in cells responding to PTH by both a stimulation of cAMP production and [Ca 2ϩ ] i . This observation raises the possibility that the pathways involved in intracellular calcium increases in one or the other cases might be different. Indeed, different mechanisms have been implicated in the stimulation of [Ca 2ϩ ] i by PTH, including an increase of intracellular calcium release in the absence (4 -6) or after stimulation of inositol phosphate (InsP s ) production (7, 8) , and the activation of calcium channels (9, 10) . The molecular basis for these differing responses has not been fully characterized, and various hypotheses are still being considered. Such differences in responses could be due to the presence of multiple PTH/PTH-related peptide (PTHrp) receptor isoforms (1) . However, a PTH/PTHrp receptor has been cloned (1, 12) , and it was subsequently demonstrated that this receptor, when expressed in transfected cells, could increase both cAMP production and [Ca 2ϩ ] i (7, 12) . In studies performed using the cloned receptor, increases in [Ca 2ϩ ] i have been shown to occur in the presence (7, 8) and the absence (5, 6) of phospholipase C activation. Thus, for at least these responses, it is not necessary to invoke different receptor isoforms to explain the activation of different signal transduction pathways by PTH. Other possible mechanisms include differences in 1) the number of receptors expressed (13) (14) (15) ; 2) cellular signal transduction machinery (13) ; and 3) the agonist used [e.g. the utilization of N-terminal, midregion or C-terminal fragments of PTH or PTHrp (16 -18) ].
We have observed a stimulation of intracellular calcium by PTH in the absence of cAMP production in a human kidney cell line otherwise able to produce both second messengers in response to other agonists. Such stimulation of intracellular calcium by PTH in the absence of stimulation of cAMP production has been previously demonstrated by Orloff et al. (3) in keratinocytes. In their studies, however, Orloff et al. did not explore the mechanisms involved in this selective PTHinduced calcium increase. The purpose of the present study was 2-fold: 1) to characterize the PTH-induced intracellular calcium increase in the human kidney cell line occurring in the absence of cAMP stimulation; 2) to investigate the molecular basis for such a response. To do so, PTH responses were compared in wild-type cells and in the same cells stably transfected by the PTH/PTHrp receptor, cells that responded to PTH with both an increase in intracellular calcium and in cAMP production. 
Materials and Methods

Peptides, reagents, and materials
Cell culture
HEK 293 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Cells were maintained in a humidified atmosphere of 95% air, 5% CO 2 , at 37 C in DMEM/HAM F12 medium supplemented with heat-inactivated newborn calf serum and FCS (5% each) and 1 mm glutamine. Certain experiments were repeated using HEK 293 cells obtained from INSERM U 344 (Paris, France) (referred to as HEK/W/U344) and cultured under the same conditions described above.
Transfection
To obtain cells stably expressing the hPTH/PTHrp receptor, wildtype HEK 293 cells from the ATCC (referred to HEK/W) were cotransfected with a pSV2 neo plasmid and 3-to 20-fold excess of a full-length hPTH/PTHrp receptor complementary DNA (cDNA) inserted in the pCDNA 1 plasmid, kindly provided by H. Jü ppner, using lipofectamine and following the manufacturer's instructions. Selection by G418 (750 g/ml) for neomycin resistance was started 24 h after transfection. PTH/PTHrp receptor-containing clones were identified by measuring the stimulation of cAMP production by a submaximal dose of hPTH(1-34) (7.2 ϫ 10 Ϫ8 m). The clone selected for this study responded to PTH by a 500-fold stimulation of cAMP production over basal levels (see Results).
Stimulation of cAMP production
Confluent cells in 24-well culture plates were stimulated by adding 5 l of 10 mm acetic acid containing 0.1% BSA in the absence (control) or with various amounts of PTH peptide to wells containing 250 l DMEM/HAM F12 supplemented with 1 mm isobutylmethylxanthine and 0.1% BSA for 10 min at 37 C as described (19) . Stock solutions of PTH peptides were prepared in 10 mm acetic acid. cAMP produced was measured using a previously described RIA after acetylation of the samples (20) . Proteins were measured with the Coomassie protein assay reagent (Pierce Chemical Co, Rockford, IL). Results are expressed as nanomoles of cAMP or picomoles of cAMP/mg protein/10 min.
Measurement of cytosolic calcium concentrations
Measurement of the cytosolic calcium concentration [Ca 2ϩ ] i was performed on cells in suspension as described (19 
Stimulation and measurement of InsP s production
InsP s production was determined as described (22) (23) (24) 4 , 5 mm glucose, 3 mm lactic acid, 10 mm sodium acetate, and 0.1% BSA (medium A). Cells were then resuspended in medium A supplemented with 10 mm LiCl and 0.1% bacitracin (3-5 ϫ 10 5 cells/ml), and incubations were performed at 30 C in the absence (basal) or presence of agonists (0.1 m hPTH(1-34), 5 min or 1 mm carbachol, 20 min). In preliminary experiments, it was determined that maximum stimulation of InsP s production was obtained 5 min after stimulation by 0.1 m hPTH(1-34) and 20 min after stimulation by 1 mm carbachol. Stimulation was stopped by adding 200 l ice-cold 5 mm EDTA-NaOH, pH 7.0, and 1 ml ice-cold chloroform-methanol (1:2 vol/vol), and placing the samples at 4 C. Chloroform (300 l) and water (300 l) were then added, and the samples were stirred and then centrifuged for 10 min at 3,000 ϫ g at 4 C to separate the phases. One milliliter of the hydrophilic phase from each sample was diluted with 3 ml of 3 mm HEPES-NaOH, pH 7.0, before chromatography. The remaining hydrophobic phase was mixed with 500 l methanol and 500 l H 2 O at 4 C and centrifuged for 5 min at 3,000 ϫ g. Radioactivity incorporated in total phosphoinositides was determined by counting the resulting lower phases after evaporating to dryness. The hydrophilic neutralized phase from each sample was applied to a chromatography column containing 0.25 g Dowex resin AG1-X8. Free inositol, glycerophosphoinositol (GroPIns), and total InsP s were successively and respectively eluted by 8 ml of the following buffers: 3 mm HEPES-NaOH pH 7.0 (inositol), 30 mm ammonium formate (GroPIns), 1 m ammonium formate, and 0.1 m formic acid (InsP s ). The radioactivity contained in each eluate and in phosphoinositide extracts was determined by scintillation spectroscopy, and the results were corrected for variable quenching. Results are presented as the ratio of the total 3 H-labeled InsP s over total incorporated radioactivity (inositolϩGroPInsϩInsP s ϩPI). The percentage of total radioactivity incorporated in inositol and GroPIns, respectively, represented 50 -75% and 0.4 -0.7% of total radioactivity and were not significantly changed by PTH stimulation.
Iodination of PTHrp(1-34)
Five micrograms of PTHrp(1-34) (Sigma) were labeled with 1 mCi [ 125 I] Na in 50 mm Na phosphate buffer (pH 7.5) with 3 ϫ 0.6 g chloramine T for 1 min at room temperature (19, 25) . The reaction was stopped with 20 l of 1 mm ␤-mercaptoethanol, 20 l of 49 mm Nacetyl-tyrosine, and 200 l of 60 mm KI. After removal of an aliquot for trichloroacetic acid precipitation, the product of iodination was purified using a SEP-PAK C18 cartridge (Waters, Milford, MA). The column was washed with 6 ml 0.1% trifluoroacetic acid (TFA) and 30 -40 ml 10% acetonitrile in 0.1% TFA, and the iodinated peptide was eluted with 40% acetonitrile in 0.1% TFA. 
I]PTHrp binding
Binding reactions were performed as described (19, 26) 
RNA extraction
Total RNA was extracted from cells grown in 56-cm 2 dishes according to the method of Chomczynski and Sacchi (27) and stored at Ϫ80 C. Messenger RNA (mRNA) was extracted from HEK/W using the Dynabeads mRNA direct kit (Dynal, Compiegne, France) following the manufacturer's instructions.
RNAse protection analysis
A 312-bp fragment of the hPTH/PTHrp receptor was amplified from the full-length PTH/PTHrp receptor cDNA inserted in the pcDNA1 plasmid using the primers C and D (Table 1 ) and cloned into the pCRII plasmid using the TA cloning system (Invitrogen, San Diego, CA). The plasmid containing the hPTH/PTHrp fragment was linearized by digestion with Spe1, and the riboprobe synthesized using T7 RNA polymerase. RNAse protection analyses were performed as described (28, 29) . The unprotected PTH/PTHrp receptor riboprope migrated at 442 bp.
Amplification of PTH/PTHrp receptor sequences by RT-PCR
cDNA was synthesized by reverse transcription of mRNA (HEK/W) and total RNA (HEK/T). Five to 10 l of cDNA were amplified in a final volume of 50 l using 1 U of Taq DNA Polymerase (GIBCO-BRL) in the presence of 1.5 mm MgCl 2 , 0.25 mm of each deoxynucleotide, and 0.5 pmol of each primer. The sequences of the oligonucleotide primers used for amplification of the hPTH/PTHrp receptor were based on the human cDNA sequence reported by Schipani et al. (30) and are described in Table 1 .
Statistical analysis
Unless otherwise stated, results are expressed as mean Ϯ sem. Statistical analyses were performed using Student's t test or analyzed by one-way ANOVA. Comparisons between individual groups were made using the Fisher least significant difference t test (31) . P values of less than 0.05 were considered as significant.
Results
PTH-induced calcium responses in HEK cells
Basal intracellular [Ca 2ϩ ] i was slightly higher in HEK/W cells compared with HEK/T cells, but the difference did not reach significance (106.6 Ϯ 15.1 and 81.5 Ϯ 3.2 nm, respectively, in HEK/W and HEK/T, n ϭ 9 -11, P Ͼ 0.05). In HEK/W and HEK/T cells, hPTH(1-34) (10 Ϫ7 m) induced a biphasic calcium response that consisted of a first transient increase with a return to baseline within 2 to 3 min followed by a second increase of lower amplitude at 4 min (Fig. 1) . The initial transient peak differed between the two cell lines both in the length of the latency period and by a modest difference in the amplitude of the response. In HEK/W cells, hPTH(1-34) produced a 1.5 Ϯ 0.2-fold increase over basal in [Ca 2ϩ ] i (peak minus basal: 57.6 Ϯ 6.0 nm, n ϭ 11) with 20 -30 sec latency period after PTH addition. In contrast, in HEK/T cells, 10 Ϫ7 m hPTH(1-34) induced an immediate transient increase with a 2.1 Ϯ 0.1-fold increase in [Ca 2ϩ ] i over basal levels (peak minus basal: 91.3 Ϯ 11.5 nm, n ϭ 9; P Ͻ 0.05 comparing HEK/W and HEK/T cells). The second rise in [Ca 2ϩ ] i was similar in both cell lines (Fig. 1) . Identical results were observed when cells were stimulated with 10 Ϫ7 m hPTHrp(1-34) and 10 Ϫ7 m hPTH(1-84) (data not shown). Bradykinin (10 Ϫ6 m), used as a control, elicited a similar increase in [Ca 2ϩ ] i in both cell lines: stimulation fold over basal: 1.67 Ϯ 0.14 (peak minus basal: 67.7 Ϯ 6.6 nm) and 1.8 Ϯ 0.8 (peak minus basal: 65.9 Ϯ 4.8 nm), respectively, in HEK/W and HEK/T cells (Fig. 1, n ϭ 9 -11 (Fig. 2) . Analysis of the data indicated that the (Fig. 4,  A and B) .
The involvement of intracellular pools of calcium in the transient calcium increases in response to PTH was further confirmed by studying PTH stimulation after intracellular calcium pools were depleted by pretreatment with carbachol. As expected from results obtained in other systems (32, 33) , carbachol alone (1 mm) induced a large transient increase in [Ca 2ϩ ] i in both cell lines ( (Fig. 5, B-D) . These results demonstrated that the transient PTH-induced calcium peaks in both HEK/W and HEK/T cells were dependent on release from intracellular calcium pools.
Pathways involved in PTH-induced calcium responses in HEK/T and HEK/W cells
Two major pools of calcium can participate in the increase of cytoplasmic calcium in response to various agonists. From which of these pools calcium is released depends on the mechanisms that are activated following stimulation (34) . One mechanism involves the activation of phospholipase C, resulting in the production of inositol trisphosphate (IP 3 ) as second messenger (34) . A second system is mediated by ryanodine receptors (RyR) (35) . To evaluate the pathway(s) involved in PTH-induced calcium responses in HEK/T and HEK/W cells, PTH stimulation was performed in cells following pretreatment with U73122 (an inhibitor of phospholipase C), ryanodine (an inhibitor of RyR), or the two agents together. U73122 (10 m) did not modify the calcium transient elicited by PTH in HEK/W cells (Fig. 6, E and F) . In contrast, U73122 totally inhibited the PTH-induced [Ca 2ϩ ] i increase in HEK/T cells (Fig. 6, A and B) . U73122 alone had no effect on basal [Ca 2ϩ ] i in either HEK/W or HEK/T cells (Fig. 6, B ryanodine, a concentration known to inhibit RyR (35), had no effect on PTH-induced increase in [Ca 2ϩ ] i (Fig. 6, C and  G) . Surprisingly, in HEK/W cells pretreated with both 100 m ryanodine and 10 m U73122, the PTH-induced increase in [Ca 2ϩ ] i was dramatically reduced (Fig. 6 , E and H, stimulation fold over basal: 1.54 compared with 1.10, respectively, in untreated and treated cells). Ryanodine alone (100 m) (Fig. 6, C and G) or in the presence of U73122 (10 m) (Fig. 6, D and H ] i in HEK/T. To further document the difference in PTH-induced calcium responses observed in HEK/T and HEK/W cells, the susceptibility of both lines to inhibition of calcium signaling in response to bradykinin was studied. In the majority of tissues, bradykinin has been reported to induce activation of phosphoinositide metabolism (37) . In contrast to the PTHinduced calcium response, the response to bradykinin was similar in both HEK/W and HEK/T cells (Fig. 1) 
PTH-induced cAMP production in HEK/W and HEK/T cells
Basal cAMP values were significantly lower in HEK/W compared with HEK/T cells (17.97 Ϯ 1.25 and 55.71 Ϯ 5.42 pmol/mg protein, respectively, n ϭ 15, P Ͻ 0.05). No significant stimulation of cAMP production by hPTH(1-34) could be detected in HEK/W for concentrations up to 2.4 ϫ 10 Ϫ7 m. A small increase was observed when cells were stimulated with 7.2 ϫ 10 Ϫ7 m hPTH (1-34) (Fig. 7 , stimulation-fold over basal: 2.27 Ϯ 0.18, n ϭ 15, P Ͻ 0.05). In contrast, hPTH(1-34) elicited a strong concentration-dependant increase in cAMP production in HEK/T cells. Maximal stimulation was obtained with 7.2 ϫ 10 Ϫ7 m hPTH(1-34) (571.7 Ϯ 56.2-fold stimulation over basal, n ϭ 9 -15). Analysis of the data indicated that the EC 50 for the stimulation of cAMP production by PTH was approximately 3 ϫ 10 Ϫ9 m. Similar results were obtained when cAMP production was stimulated with hPTHrp(1-34) or hPTH(1-84) (data not shown). Carbachol pretreatment did not significantly modify PTHinduced stimulation of cAMP production ( 
Characterization of [ 125 I]PTHrP(1-34) binding to HEK/W and HEK/T cells
No specific binding of [
125 I]PTHrp(1-34) could be detected in HEK/W cells (Fig. 8) . As expected, specific binding of [ 
Expression of PTH/PTHrp receptor mRNA in HEK/W and HEK/T cells
To study PTH/PTHrp receptor mRNA expression, RNAse protection analysis was performed on total RNA from HEK/W and HEK/T cells using a human PTH/PTHrp receptor probe specific for a 312-bp fragment coding for a portion of the N-terminal extracellular domain of the receptor. Results clearly demonstrated the presence of a specific signal for the PTH/PTHrp receptor mRNA in HEK/W cells (Fig. 9) . The intensity of the signal was proportional to the quantity of total RNA used in the assay. No signal was detected in HEK/W using 5 g RNA, while 50 and 100 g RNA gave signals of increasing intensity. Similar results were obtained with the HEK/W/U344. As expected, an intense signal was obtained when as little as 10 g RNA from HEK/T cells was used (Fig. 9) .
To further characterize the PTH/PTHrp receptor mRNA expressed in HEK/W cells, cDNA was prepared from HEK/W and HEK/T cells and used as a substrate to amplify the entire PTH/PTHrp receptor sequence in three overlapping fragments, using three pairs of primers (C/B, E/F, I/J) ( Table 1 ). The pair C/B amplifies exons S, E1, E2, and the beginning of exon G [according to the nomenclature of Kong et al. (38) ], the pair E/F extends from exon E1 to the junction of exon M3/M4, and the pair I/J extends from exon M3 to the end of exon T (Table 1) . When the pairs E/F and I/J were used, amplification products obtained for cDNA from HEK/W and HEK/T cells migrated as single bands of expected size (871 and 1010 bp, respectively) (Fig. 10) . When the pair C/B was used, a single band of expected size (451 bp) was obtained in the HEK/T, while in the HEK/W, a smaller amplification product migrating between 300 and 400 bp was detected in addition to the 451-bp product. This smaller amplification product corresponds to the amplification of a previously described alternatively spliced mRNA of the PTH/PTHrp receptor (19) .
Discussion
These results demonstrated that 1) in the untransfected human embryonic kidney cell line HEK293 the agonists PTH(1-34), PTHrp(1-34), and PTH(1-84) increased [Ca 2ϩ ] i , but did not stimulate cAMP and InsP s production; 2) these cells expressed PTH/PTHrp receptor mRNA, although no binding of iodinated PTHrp(1-34) could be detected; 3) in the same cell line transfected by the PTH/PTHrp receptor and expressing a high number of receptors, PTH agonists increased [Ca 2ϩ ] i via a phospholipase C sensitive pathway and stimulated cAMP and InsP s production.
We found a readily observable, reproducible, and sensitive stimulation of intracellular [Ca 2ϩ ] i in wild-type HEK293 cells obtained from two different sources. In addition, the presence of PTH/PTHrp receptor mRNA was clearly identified in the cells by RT-PCR and RNAse protection analysis. Our results contrast with previously published work reporting the absence of a PTH-induced increase in intracellular [Ca 2ϩ ] i in wild-type HEK293 cells (8, 39) , and the absence of PTH/ PTHrp receptor mRNA expression evaluated by Northern blotting (40) . The reasons for the discrepancy between these and our results remain unclear. Nevertheless, the demonstration in this human renal cell line of a robust, reproducible, and sensitive PTH-induced increase in [Ca 2ϩ ] i permitted the further characterization of PTH-induced calcium release occurring in the absence of stimulation of cAMP production. Ϫ8 M hPTH(1-34) (PTH), 100 M carbachol (carbachol), and pretreated by carbachol for 4 min before PTH stimulation (carbachol ϩ PTH).
a Results are expressed as picomoles of cAMP/mg protein and are the mean Ϯ SD, n ϭ 3. In HEK/W cells, PTH-induced increases in [Ca 2ϩ ] i were observed for PTH concentrations as low as 10 Ϫ9 m. In contrast, PTH in concentrations as high as 2.4 ϫ 10 Ϫ7 m did not stimulate cAMP production. The absence of stimulation of cAMP production could not be explained by a deficiency in the Gs/adenylate-cyclase system, as PGE 2 and forskolin stimulated cAMP production under the same assay conditions. In addition, PTH-stimulated cAMP production was easily detected in the same HEK293 cells following transfection with a plasmid that induced the expression of large numbers of PTH/PTHrp receptors (see below). These results are similar to those obtained by Orloff et al. (3) ] i increases showed that in both HEK/W and/T cell lines, PTH agonists induced a biphasic stimulation: a transient peak with a return to baseline followed by a slow linear increase over time. The initial increase was due to calcium release from intracellular stores, as it resisted quenching of calcium in the extracellular buffer and was abolished by prior emptying of the intracellular calcium stores. Although the transient peak in [Ca 2ϩ ] i was due to a release from intracellular stores in both HEK/W and HEK/T cells, the response differed in both time course and magnitude, suggesting that the pathways involved in the PTH-induced calcium response were different in the two cell lines. In support of this hypothesis, the phospholipase C inhibitor U73122 inhibited the PTH-induced calcium increase in the HEK/T cells, but not in the HEK/W cells. Furthermore, PTH-stimulated InsP s production was detected in the HEK/T but not in HEK/W cells. In both cell lines, significant formation of InsP s in response to carbachol could be detected, demonstrating that this signaling pathway was potentially operational in both cell lines. Interestingly, ryanodine, when added with the phospholipase C inhibitor U73122, inhibited PTH-induced calcium increase in HEK/W cells, indicating that activation of the RyR plays a role in the PTH-induced calcium release in HEK/W cells. Taken together, these data clearly demonstrate that the pathways involved in PTH-induced calcium release in HEK/W and HEK/T cells are different and suggest that PLC activation is the dominant pathway in HEK/T cells, but not in HEK/W cells. Although clearly not the dominant pathway responsible for the release of [Ca 2ϩ ] i from HEK/W cells, it is possible that low levels of IP 3 production occurred in these cells but were below the sensitivity of the assays used in our study. In particular, the requirement for both ryanodine and U73122 to inhibit calcium release by HEK/W cells is compatible with this possibility. Measurement of the IP 3 6) . Oligonucleotide pairs C/B, E/F, and I/J are described in Table 1 , and amplify the entire receptor cDNA in three overlapping fragments. Amplified products were separated on a 1% agarose gel and stained with ethidium bromide. The mol wt markers are a 100-bp ladder (lanes mw). fraction of InsP s , a more sensitive approach for the detection of IP 3 production, might be useful in resolving this issue.
Until recently, the production of IP 3 appeared to account for calcium release from intracellular stores in non-muscle cells in most cases. It is now clear, however, that several independent pathways exist, and that agonist-induced calcium release from intracellular stores may occur without a rise in intracellular InsP s . To our knowledge, the present study is the first to demonstrate ryanodine-sensitive calcium release triggered by PTH.
Differences in the expression of activities involved in the transduction of signals through the PTH/PTHrp receptor and presence of PTH/PTHrp receptor isoforms have both been proposed to explain the selective activation of a single transducing pathway following PTH stimulation. In this study, two cell lines, differing only by the level of PTH/PTHrp receptor expression, were compared. It is difficult to exclude the possibility that transfection of cells with the PTH/PTHrp receptor did not modify activities necessary for signal transduction, and such effects could contribute to the differences observed in our study. Nevertheless, both HEK/T and HEK/W cells had an equivalent capacity to generate cAMP and increase [Ca 2ϩ ] i in response to other agonists, suggesting that changes in postreceptor signal transduction are unlikely to entirely explain the differences observed in these two cell lines in response to PTH. In regard to PTH/PTHrp receptor isoform expression, several findings in our study argue against the expression of a PTH/PTHrp receptor isoform that differs from the classic type I PTH/PTHrp receptor. First, a similar increase in [Ca 2ϩ ] i was obtained by PTH and PTHrp, demonstrating that the PTH receptor involved recognized both PTH and PTHrp, as demonstrated for the classic PTH/PTHrp receptor (1). The receptor involved thus was not the type II PTH receptor (41) . Second, a PTH-stimulated increase in [Ca 2ϩ ] i was produced by a N-terminal fragment of PTH (and PTHrp), not by C-terminal or midregion fragments, indicating that a PTH receptor isoform specifically recognizing C-or midregion PTH fragments was not involved (16 -18 34 ]bPTH(7-34)amide). This confirmed that the PTH effect was mediated by a classic PTH receptor that bound and was activated by the N-terminal portion of the molecule. Fourth, PTH/PTHrp receptor mRNA was clearly demonstrated using a RNAse protection assay and RT-PCR. Furthermore, no other amplification products suggesting the presence of other functional receptor isoforms were detected. In this context, it is noteworthy that we (19) and others (42) have not been able to identify the presence of functional isoforms resulting from alternate splicing of the PTH/PTHrp receptor, other than the isoform identified by Jü ppner et al. (12) . Of course, none of these findings conclusively identifies the PTH/ PTHrp receptor as the initiator of the response observed. Nevertheless, taken together, these results strongly suggest that the PTH-induced increase in [ Our results provide a third possible explanation for the seemingly discrepant results obtained in prior studies; that is, a regulation by receptor number of the transduction signals activated. Such a regulation by receptor number has been demonstrated for the PTH/PTHrp receptor (1, 15) and for other receptors (14) . It is usually accepted that PTH stimulation of an IP 3 response requires a higher level of receptor expression than PTH stimulation of cAMP production. Our results are in agreement with these results, as we detected InsP s production in response to PTH only in cells expressing a high level of receptors. The results presented here extend that observation, however, and suggest that the differing PTH responses demonstrated in HEK/W and HEK/T cells are determined by the level of PTH/PTHrp receptor expression in such a way that PTH induces an increase in [Ca 2ϩ ] i in the absence of either InsP s or cAMP production in cells expressing low numbers of PTH/PTHrp receptors through a pathway sensitive to ryanodine, while in cells expressing a high number of receptors, PTH can stimulate cAMP production and induces calcium release through an increase in the production of InsP s . Consistent with this hypothesis, PTH-induced calcium release was previously demonstrated to be associated with phospholipase C activation in HEK293 cells transfected with the PTH/PTHrp receptor and expressing 4 ϫ 10 6 receptors per cell (7), but to occur in the absence of phospholipase C activation in cells expressing 1.5 ϫ 10 5 receptors per cell (5) . Interestingly, the ryanodine-sensitive pathway for calcium release is no longer detected in cells expressing large numbers of PTH/PTHrp receptors. The extinction of this pathway is not likely to be a direct effect of an increase in receptor number, but may result from other changes in PTH signaling induced by the increased number of receptors.
In conclusion, our data suggest that changes in PTH/ PTHrp receptor number can modify both the extent of calcium signaling via phospholipase C and ryanodine receptor pathways, as well as the stimulation of cAMP production by PTH. As PTH/PTHrp receptor number and PTH effects vary as a function of cell differentiation, this may be one of the molecular mechanisms through which PTH effects are regulated.
